Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Teladoc Is Still a Great Healthcare Stock to Buy for 2021 and Beyond

By Rachel Warren and Brian Withers – Sep 29, 2021 at 9:45AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The telehealth giant's growth story isn't over yet.

Teladoc (TDOC 2.42%) was one of the hottest of the work-from-home stocks in the early days of the pandemic. But now, with more people back in the office and going to the doctor in-person again, some investors might be wondering whether Teladoc is still a good long-term investment or not.

In this segment of Backstage Pass, recorded on Sept. 20, Fool contributors Rachel Warren and Brian Withers share what they love about this high-growth healthcare stock and why they think it has plenty of runway left. 


10 stocks we like better than Teladoc Health
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Teladoc Health wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks


*Stock Advisor returns as of September 17, 2021


Rachel Warren: It's another one of those companies that already had a really strong history of growth before the pandemic. In 2019, it grew its revenue 32%, 98% jump in 2020, of course, with so many people at home. But then even just the first two quarters of this year, it grew its revenue by triple-digit percentages. 

It's continuing to build upon this really strong track record of growth, and even now with more people, it will be much easier to go to the doctor and you get those appointments that might have been put off before. It's continuing to see these massive growth numbers. 

I like the business. I think it takes time and patience to experience meaningful returns. I think this is one of those companies that it's probably not going to replicate those same jumps that we saw in 2020 where shares just skyrocketed. But if you look back over the last five years and not just the period over a few months, I think the stock can definitely replicate that, and then some over the next five to 10 years.

Brian Withers: Yeah, I can't imagine. You know, similar to when people first discover the convenience of e-commerce, we've all probably had to experience virtual telehealth visits just because of so many physicians offices and specialty offices have closed. 

To me, it's so [laughs] much easier just to instead of driving to the office and waiting and doing all that stuff and taking two hours for a 30 minute visit with the doctor, you can take 35 minutes and do it from your home. Absolutely, I think that the market has thrown this out as a coronavirus stock, but I'm with you. I think this one has got a long way to run.

Rachel Warren owns shares of Teladoc Health. The Motley Fool owns shares of and recommends Teladoc Health. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teladoc Health Stock Quote
Teladoc Health
$27.13 (2.42%) $0.64

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.